How did RGDXQ's recent EPS compare to expectations?
The most recent EPS for Response Genetics Inc is $, expectations of $.
How did Response Genetics Inc RGDXQ's revenue perform in the last quarter?
Response Genetics Inc revenue for the last quarter is $
What is the revenue estimate for Response Genetics Inc?
According to of Wall street analyst, the revenue estimate of Response Genetics Inc range from $ to $
What's the earning quality score for Response Genetics Inc?
Response Genetics Inc has a earning quality score of A-/58.467064. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Response Genetics Inc report earnings?
Response Genetics Inc next earnings report is expected in
What are Response Genetics Inc's expected earnings?
Response Genetics Inc expected earnings is $, according to wall-street analysts.
Did Response Genetics Inc beat earnings expectations?
Response Genetics Inc recent earnings of $ expectations.
Key Stats
Prev.Close
$0.0001
Open
$0
Day's Range
$0 - $0.0001
52 week range
$0 - $0.0001
Volume
77.0K
Avg.Volume
2.5K
Dividend yield
--
EPS (TTM)
-0.54
Market Cap
$3.8K
What is RGDXQ?
Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California and currently employs 96 full-time employees. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.